CEO Pens Management Piece Featured in Life Science Leader

NEW YORK - April 28, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company reports the Company's CEO was featured in an article he wrote on venture capital titled Accelerators Enter When VCs Fear To Tread:

http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001

Life Science Leader magazine is an essential business journal for life science executives who work for everything from emerging biotechs to Big Pharmas. Their content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses.

Each month, Life Science Leader features interviews with executives from the leading pharma and biotech companies, including Pfizer, Merck, Daiichi Sankyo, Genentech, Genzyme, Eli Lilly, and Janssen, as well as the FDA and more. This exclusive thought leadership provides an in-depth look into industry trends and hot topics that will impact the growth of the pharma and biopharma markets. As the market is continually growing and innovating, these insights provide readers with actionable information and strategies to implement when navigating the evolving clinical, manufacturing, entrepreneurial, and regulatory landscapes.

Corin explains how times have changed for start-up biotechnology companies, though, and the challenges have grown in magnitude. These days, the very same venture capital firms that would hand out a few dollars in the early stages now are idling their time, investing much bigger sums only after much more development has occurred.

In the article, Corin leverages his expertise at Q BioMed Inc., where he focuses on acquiring licenses to innovative biomedical assets in the private company space or academic setting.

"Our team at Q Bio are dedicated to providing those developers with the strategic resources, developmental support, and expansion capital to ensure they meet their potential, with the ultimate goal of enabling them to provide products to patients in need. Our mission is to license and acquire innovative life sciences assets and accelerate their product development timelines to commercialize their drug candidates and devices or bring them to the next level in terms of valuation inflection and the attention of the larger Pharma players or IPO them as stand-alone companies or just grow a revenue model organically", states Corin.

Excerpt from the article:

"Most venture funds, for example, have become increasingly impatient to harvest returns from their investments, many expecting an 'exit' within only 2-4 years. This trend has been adverse for many biomedical technologies, since they generally have a much longer gestation cycle than communications, electronics or information technologies. In addition, many biomedical technologies require regulatory approvals, which further increases development costs and lengthens the investment cycle."

The one thing that really has not changed is the amount of equity the venture capitalists want when they finally do invest. For those who are only interested in getting their idea into the marketplace, giving up 80 or 90% of their company may be acceptable. Jonas Salk refused to patent his polio vaccine because his focus was preventing that disease and not making billions for himself. Handing off the headaches of running a business to people who studied accounting and marketing rather than organic chemistry and electrical engineering may be the solution for many researchers.

To read the entire article, please follow this link

http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001

About Q BioMed Inc.

Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Read this news in full at http://www.investorideas.com/CO/QBIO/news/2016/04281.asp

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435 

This email address is being protected from spambots. You need JavaScript enabled to view it.
http://www.qbiomed.com

 

Visit this Company: http://www.qbiomed.com

 

More info on QBIO at Investorideas.com: http://www.investorideas.com/CO/QBIO/

 

Sign up for the free investor news and stock alerts:

http://www.investorideas.com/Resources/Newsletter.asp

 

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

 

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.